oral HIF-PHD enzyme inhibitor

Ph. III candidate for anemia in CKD

carboxylic acid class of HIF-PHD inhibitors

J. Pharmacol. Exp. Ther.

Akebia Therapeutics, Cambridge, MA

Vadadustat chemical structure oral HIF-PHD enzyme inhibitor - Akebia Therapeutics, Cambridge, MA

Context. Vadadustat (Akebia Therapeutics) is an oral hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) inhibitor being developed for anemia in patients with chronic kidney disease (CKD). HIFs are transcription factors that…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: